vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and UNITED GUARDIAN INC (UG). Click either name above to swap in a different company.
UNITED GUARDIAN INC is the larger business by last-quarter revenue ($3.0M vs $2.5M, roughly 1.2× Bolt Biotherapeutics, Inc.). Over the past eight quarters, UNITED GUARDIAN INC's revenue compounded faster (-4.6% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
The Guardian Life Insurance Company of America is one of the largest mutual life insurance companies in the world. Based in Manhattan, it has approximately 8,000 employees in the United States, and a network of over 3,000 financial representatives in more than 70 agencies nationwide. As of 2018, it ranks 239th on the Fortune 500 list of largest American corporations by revenue. In 2015, Guardian achieved the highest earnings in its 155-year history with $7.3 billion in capital and $1.5 billio...
BOLT vs UG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $3.0M |
| Net Profit | $-6.6M | — |
| Gross Margin | — | 45.0% |
| Operating Margin | -283.4% | 24.4% |
| Net Margin | -265.2% | — |
| Revenue YoY | — | 19.6% |
| Net Profit YoY | 58.4% | — |
| EPS (diluted) | $-9.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $3.0M | ||
| Q3 25 | $2.2M | $2.3M | ||
| Q2 25 | $1.8M | $2.8M | ||
| Q1 25 | $1.2M | $2.5M | ||
| Q4 24 | $0 | $2.5M | ||
| Q3 24 | $1.1M | $3.1M | ||
| Q2 24 | $1.3M | $3.4M | ||
| Q1 24 | $5.3M | $3.3M |
| Q4 25 | $-6.6M | — | ||
| Q3 25 | $-7.1M | $268.4K | ||
| Q2 25 | $-8.6M | $626.8K | ||
| Q1 25 | $-11.0M | $560.9K | ||
| Q4 24 | $-15.9M | — | ||
| Q3 24 | $-15.2M | $865.5K | ||
| Q2 24 | $-21.2M | $956.2K | ||
| Q1 24 | $-10.8M | $925.4K |
| Q4 25 | — | 45.0% | ||
| Q3 25 | — | 42.1% | ||
| Q2 25 | — | 52.8% | ||
| Q1 25 | — | 54.7% | ||
| Q4 24 | — | 51.7% | ||
| Q3 24 | — | 54.0% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 52.2% |
| Q4 25 | -283.4% | 24.4% | ||
| Q3 25 | -355.1% | 9.5% | ||
| Q2 25 | -510.5% | 24.5% | ||
| Q1 25 | -991.4% | 24.6% | ||
| Q4 24 | — | 22.5% | ||
| Q3 24 | -1441.1% | 31.0% | ||
| Q2 24 | -1772.3% | 32.9% | ||
| Q1 24 | -324.1% | 31.5% |
| Q4 25 | -265.2% | — | ||
| Q3 25 | -329.4% | 11.9% | ||
| Q2 25 | -474.6% | 22.1% | ||
| Q1 25 | -903.4% | 22.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1330.1% | 28.3% | ||
| Q2 24 | -1662.4% | 28.2% | ||
| Q1 24 | -205.0% | 28.4% |
| Q4 25 | $-9.38 | — | ||
| Q3 25 | $-3.72 | — | ||
| Q2 25 | $-4.46 | — | ||
| Q1 25 | $-0.29 | — | ||
| Q4 24 | $-13.73 | — | ||
| Q3 24 | $-7.93 | — | ||
| Q2 24 | $-11.12 | — | ||
| Q1 24 | $-0.28 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $11.2M |
| Total Assets | $56.7M | $13.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $8.6M | ||
| Q3 25 | $31.9M | $8.3M | ||
| Q2 25 | $34.8M | $8.4M | ||
| Q1 25 | $38.8M | $8.1M | ||
| Q4 24 | $47.3M | $9.4M | ||
| Q3 24 | $53.8M | $9.5M | ||
| Q2 24 | $73.7M | $9.9M | ||
| Q1 24 | $91.3M | $8.6M |
| Q4 25 | $26.5M | $11.2M | ||
| Q3 25 | $32.1M | $10.6M | ||
| Q2 25 | $38.8M | $11.5M | ||
| Q1 25 | $46.8M | $10.8M | ||
| Q4 24 | $57.2M | $11.9M | ||
| Q3 24 | $72.0M | $11.4M | ||
| Q2 24 | $85.9M | $12.1M | ||
| Q1 24 | $104.2M | $11.2M |
| Q4 25 | $56.7M | $13.1M | ||
| Q3 25 | $65.1M | $12.2M | ||
| Q2 25 | $75.5M | $13.4M | ||
| Q1 25 | $85.9M | $12.8M | ||
| Q4 24 | $99.6M | $13.8M | ||
| Q3 24 | $109.3M | $13.3M | ||
| Q2 24 | $124.2M | $13.8M | ||
| Q1 24 | $142.9M | $13.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $330.5K |
| Free Cash FlowOCF − Capex | — | $308.0K |
| FCF MarginFCF / Revenue | — | 10.4% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $330.5K | ||
| Q3 25 | $-9.7M | $1.0M | ||
| Q2 25 | $-9.6M | $303.2K | ||
| Q1 25 | $-13.4M | $322.1K | ||
| Q4 24 | $-14.4M | $269.3K | ||
| Q3 24 | $-14.0M | $1.2M | ||
| Q2 24 | $-16.1M | $1.3M | ||
| Q1 24 | $-16.8M | $644.1K |
| Q4 25 | — | $308.0K | ||
| Q3 25 | — | $995.8K | ||
| Q2 25 | — | $285.6K | ||
| Q1 25 | — | $318.5K | ||
| Q4 24 | — | $-45.9K | ||
| Q3 24 | $-14.0M | $1.2M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $622.2K |
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 10.1% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | -1.9% | ||
| Q3 24 | -1227.6% | 39.2% | ||
| Q2 24 | — | 37.1% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | 3.6% | 1.0% | ||
| Q2 24 | 0.0% | 1.9% | ||
| Q1 24 | 0.0% | 0.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.77× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.38× | ||
| Q1 24 | — | 0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOLT
Segment breakdown not available.
UG
| Pharmaceuticals | $1.6M | 53% |
| Other | $1.4M | 47% |
